13.48
price down icon6.65%   -0.96
after-market After Hours: 13.50 0.02 +0.15%
loading
Viridian Therapeutics Inc stock is traded at $13.48, with a volume of 983.56K. It is down -6.65% in the last 24 hours and down -13.20% over the past month.
See More
Previous Close:
$14.44
Open:
$13.98
24h Volume:
983.56K
Relative Volume:
1.03
Market Cap:
$1.26B
Revenue:
$288.00K
Net Income/Loss:
$-228.06M
P/E Ratio:
-3.1718
EPS:
-4.25
Net Cash Flow:
$-168.82M
1W Performance:
-12.81%
1M Performance:
-13.20%
6M Performance:
-40.75%
1Y Performance:
-23.02%
1-Day Range:
Value
$13.23
$13.98
1-Week Range:
Value
$13.23
$15.44
52-Week Range:
Value
$11.40
$27.20

Viridian Therapeutics Inc Stock (VRDN) Company Profile

Name
Name
Viridian Therapeutics Inc
Name
Phone
617.272.4600
Name
Address
221 CRESCENT STREET, WALTHAM
Name
Employee
0
Name
Twitter
Name
Next Earnings Date
2024-11-11
Name
Latest SEC Filings
Name
VRDN's Discussions on Twitter

Compare VRDN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
VRDN
Viridian Therapeutics Inc
13.48 1.26B 288.00K -228.06M -168.82M -4.25
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-19-24 Downgrade Wells Fargo Overweight → Equal Weight
Nov-25-24 Initiated TD Cowen Buy
Sep-11-24 Reiterated Needham Buy
Jun-11-24 Initiated Wolfe Research Outperform
Jun-06-24 Initiated Goldman Buy
May-09-24 Downgrade B. Riley Securities Buy → Neutral
May-09-24 Downgrade Ladenburg Thalmann Buy → Neutral
Jun-14-23 Initiated BTIG Research Buy
Jun-14-23 Resumed Credit Suisse Outperform
May-30-23 Initiated RBC Capital Mkts Outperform
Apr-17-23 Initiated Wells Fargo Overweight
Mar-30-23 Initiated Stifel Buy
Dec-19-22 Initiated Cowen Outperform
Dec-19-22 Initiated Needham Buy
Dec-16-22 Initiated Credit Suisse Outperform
Dec-01-22 Initiated H.C. Wainwright Buy
Jun-23-22 Initiated B. Riley Securities Buy
Nov-18-21 Initiated SVB Leerink Outperform
Oct-12-21 Initiated Evercore ISI Outperform
Jan-25-21 Initiated Ladenburg Thalmann Buy
View All

Viridian Therapeutics Inc Stock (VRDN) Latest News

pulisher
03:58 AM

Quantbot Technologies LP Invests $164,000 in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World

03:58 AM
pulisher
Mar 28, 2025

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Acquired by Swiss National Bank - Defense World

Mar 28, 2025
pulisher
Mar 25, 2025

Raymond James Financial Inc. Makes New $6.02 Million Investment in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World

Mar 25, 2025
pulisher
Mar 24, 2025

Where are the Opportunities in (VRDN) - news.stocktradersdaily.com

Mar 24, 2025
pulisher
Mar 22, 2025

Charles Schwab Investment Management Inc. Raises Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World

Mar 22, 2025
pulisher
Mar 21, 2025

AlphaQuest LLC Acquires 1,519 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World

Mar 21, 2025
pulisher
Mar 20, 2025

Commit To Buy Viridian Therapeutics At $12.50, Earn 13.2% Annualized Using Options - Nasdaq

Mar 20, 2025
pulisher
Mar 20, 2025

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Purchased by Bank of New York Mellon Corp - Defense World

Mar 19, 2025
pulisher
Mar 16, 2025

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Bought by Arizona State Retirement System - Defense World

Mar 16, 2025
pulisher
Mar 15, 2025

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Mar 15, 2025
pulisher
Mar 15, 2025

410,440 Shares in Viridian Therapeutics, Inc. (NASDAQ:VRDN) Acquired by Victory Capital Management Inc. - Defense World

Mar 15, 2025
pulisher
Mar 12, 2025

Viridian Therapeutics at Leerink’s Conference: Progress in TED Treatments By Investing.com - Investing.com UK

Mar 12, 2025
pulisher
Mar 10, 2025

Viridian Therapeutics appoints new director, sees board resignation By Investing.com - Investing.com South Africa

Mar 10, 2025
pulisher
Mar 10, 2025

Viridian Therapeutics Announces Inducement Stock Option Grants - Nasdaq

Mar 10, 2025
pulisher
Mar 10, 2025

Viridian Therapeutics appoints new director, sees board resignation - Investing.com India

Mar 10, 2025
pulisher
Mar 06, 2025

What is B. Riley’s Forecast for VRDN Q1 Earnings? - Defense World

Mar 06, 2025
pulisher
Mar 05, 2025

Principal Financial Group Inc. Has $3.42 Million Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World

Mar 05, 2025
pulisher
Mar 05, 2025

What is B. Riley’s Estimate for VRDN Q2 Earnings? - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

Decoding Viridian Therapeutics Inc (VRDN): A Strategic SWOT Insi - GuruFocus.com

Mar 04, 2025
pulisher
Mar 04, 2025

Viridian Therapeutics inks new $300M sales agreement By Investing.com - Investing.com South Africa

Mar 04, 2025
pulisher
Mar 04, 2025

Viridian Therapeutics Terminates Prior $175 Million Sale Agreement -March 04, 2025 at 06:36 am EST - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Viridian Therapeutics Enters New $300M Sale Agreement - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Viridian Therapeutics inks new $300M sales agreement - Investing.com

Mar 04, 2025
pulisher
Mar 04, 2025

Rhumbline Advisers Has $1.92 Million Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World

Mar 04, 2025
pulisher
Mar 04, 2025

Viridian Therapeutics Faces Uncertainty Amid Regulatory Approval Challenges - TipRanks

Mar 04, 2025
pulisher
Mar 03, 2025

Viridian Therapeutics, Inc.\DE SEC 10-K Report - TradingView

Mar 03, 2025
pulisher
Mar 03, 2025

Q1 EPS Estimates for Viridian Therapeutics Raised by Wedbush - Defense World

Mar 03, 2025
pulisher
Mar 02, 2025

How to Take Advantage of moves in (VRDN) - Stock Traders Daily

Mar 02, 2025
pulisher
Mar 02, 2025

Viridian Therapeutics: Positive Data In TED, Strong Cash Position, 1.5-Year Window - Seeking Alpha

Mar 02, 2025
pulisher
Mar 02, 2025

FY2027 EPS Forecast for Viridian Therapeutics Cut by Analyst - Defense World

Mar 02, 2025
pulisher
Feb 28, 2025

Viridian Therapeutics (NASDAQ:VRDN) Posts Earnings Results, Beats Expectations By $0.24 EPS - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

RBC Capital Adjusts Viridian Therapeutics Price Target to $46 From $47, Maintains OutperformSpeculative Risk Rating - Marketscreener.com

Feb 28, 2025
pulisher
Feb 28, 2025

Viridian Therapeutics: Promising Market Position and Growth Prospects Justify Buy Rating - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

Viridian Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance UK

Feb 28, 2025
pulisher
Feb 28, 2025

Viridian Therapeutics Reports Strong Progress and Financials - TipRanks

Feb 28, 2025
pulisher
Feb 27, 2025

Viridian Therapeutics: Strong Financials and Promising Clinical Developments Drive Buy Rating - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Lags Revenue Estimates - MSN

Feb 27, 2025
pulisher
Feb 27, 2025

Viridian Therapeutics reports Q4 EPS (81c), consensus ($1.04) - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Viridian Therapeutics Positioned for Market Leadership with Strategic Advancements and Competitive Edge - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Viridian Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 27, 2025
pulisher
Feb 27, 2025

VRDNViridian Therapeutics Inc Latest Stock News & Market Updates - StockTitan

Feb 27, 2025
pulisher
Feb 27, 2025

Viridian Therapeutics: Strong TED Trial Results and Promising Pipeline Drive Buy Rating - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Viridian Therapeutics' Q4 Net Loss Narrows, Revenue Flat -February 27, 2025 at 09:27 am EST - Marketscreener.com

Feb 27, 2025
pulisher
Feb 27, 2025

Earnings Flash (VRDN) Viridian Therapeutics Posts Q4 Revenue $72,000 -February 27, 2025 at 07:20 am EST - Marketscreener.com

Feb 27, 2025
pulisher
Feb 27, 2025

Earnings Flash (VRDN) Viridian Therapeutics Posts Q4 Net Loss $0.81 a Share, vs. FactSet Est of $1.05 Loss - Marketscreener.com

Feb 27, 2025
pulisher
Feb 27, 2025

Viridian Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView

Feb 27, 2025
pulisher
Feb 27, 2025

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results - Business Wire

Feb 27, 2025
pulisher
Feb 25, 2025

Viridian Therapeutics Becomes Oversold (VRDN) - Nasdaq

Feb 25, 2025
pulisher
Feb 23, 2025

Viridian Therapeutics (VRDN) Projected to Post Quarterly Earnings on Tuesday - Defense World

Feb 23, 2025
pulisher
Feb 23, 2025

Analysts Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) Price Target at $35.70 - MarketBeat

Feb 23, 2025

Viridian Therapeutics Inc Stock (VRDN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
Cap:     |  Volume (24h):